ImmuPharma plc (IMM.L)
- Previous Close
2.1400 - Open
2.1700 - Bid 2.1000 x --
- Ask 2.3000 x --
- Day's Range
2.1141 - 2.2810 - 52 Week Range
0.8220 - 3.8000 - Volume
604,698 - Avg. Volume
2,716,966 - Market Cap (intraday)
8.912M - Beta (5Y Monthly) 1.47
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
www.immupharma.co.ukRecent News: IMM.L
Performance Overview: IMM.L
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMM.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMM.L
Valuation Measures
Market Cap
8.91M
Enterprise Value
8.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
100.06
Price/Book (mrq)
5.13
Enterprise Value/Revenue
124.38
Enterprise Value/EBITDA
-2.26
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.90%
Return on Equity (ttm)
-159.35%
Revenue (ttm)
69.96k
Net Income Avi to Common (ttm)
-2.99M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
210.58k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.48M
Research Analysis: IMM.L
Company Insights: IMM.L
IMM.L does not have Company Insights